CN104127417B - 一种氨酚咖那敏片及其制备方法 - Google Patents
一种氨酚咖那敏片及其制备方法 Download PDFInfo
- Publication number
- CN104127417B CN104127417B CN201410380073.8A CN201410380073A CN104127417B CN 104127417 B CN104127417 B CN 104127417B CN 201410380073 A CN201410380073 A CN 201410380073A CN 104127417 B CN104127417 B CN 104127417B
- Authority
- CN
- China
- Prior art keywords
- parts
- coating
- quick
- preparation
- acetaminophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- XABJJJZIQNZSIM-UHFFFAOYSA-N azane;phenol Chemical compound [NH4+].[O-]C1=CC=CC=C1 XABJJJZIQNZSIM-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 235000016213 coffee Nutrition 0.000 title claims abstract description 41
- 235000013353 coffee beverage Nutrition 0.000 title claims abstract description 41
- 238000000576 coating method Methods 0.000 claims abstract description 103
- 239000011248 coating agent Substances 0.000 claims abstract description 96
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 88
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229960005489 paracetamol Drugs 0.000 claims abstract description 42
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960001948 caffeine Drugs 0.000 claims abstract description 37
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 37
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 34
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 31
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 17
- 229920002472 Starch Polymers 0.000 claims abstract description 17
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 17
- 239000011734 sodium Substances 0.000 claims abstract description 17
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 17
- 239000008107 starch Substances 0.000 claims abstract description 17
- 235000019698 starch Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 51
- 235000010603 pastilles Nutrition 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 15
- 238000000889 atomisation Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 32
- 238000005516 engineering process Methods 0.000 abstract description 15
- 238000004090 dissolution Methods 0.000 abstract description 11
- 206010022000 influenza Diseases 0.000 abstract description 7
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 4
- 208000036071 Rhinorrhea Diseases 0.000 abstract description 4
- 206010039101 Rhinorrhoea Diseases 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 206010019233 Headaches Diseases 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 3
- 231100000869 headache Toxicity 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 3
- 240000007154 Coffea arabica Species 0.000 description 34
- 239000000243 solution Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 18
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 238000013112 stability test Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380073.8A CN104127417B (zh) | 2014-08-05 | 2014-08-05 | 一种氨酚咖那敏片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410380073.8A CN104127417B (zh) | 2014-08-05 | 2014-08-05 | 一种氨酚咖那敏片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104127417A CN104127417A (zh) | 2014-11-05 |
CN104127417B true CN104127417B (zh) | 2016-04-20 |
Family
ID=51800441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410380073.8A Active CN104127417B (zh) | 2014-08-05 | 2014-08-05 | 一种氨酚咖那敏片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104127417B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112472678A (zh) * | 2020-11-12 | 2021-03-12 | 澳美制药厂有限公司 | 肾素那敏制剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102349915A (zh) * | 2011-08-16 | 2012-02-15 | 石药集团中诺药业(石家庄)有限公司 | 一种氨酚咖敏维c制剂及其制备方法 |
CN102861106A (zh) * | 2012-09-25 | 2013-01-09 | 海南葫芦娃制药有限公司 | 一种复方氨酚烷胺微丸的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008302460A1 (en) * | 2007-09-17 | 2009-03-26 | Mcneil-Ppc, Inc. | Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum |
-
2014
- 2014-08-05 CN CN201410380073.8A patent/CN104127417B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102349915A (zh) * | 2011-08-16 | 2012-02-15 | 石药集团中诺药业(石家庄)有限公司 | 一种氨酚咖敏维c制剂及其制备方法 |
CN102861106A (zh) * | 2012-09-25 | 2013-01-09 | 海南葫芦娃制药有限公司 | 一种复方氨酚烷胺微丸的制备方法 |
Non-Patent Citations (1)
Title |
---|
复方氨酚那敏缓释片的含量测定;王润玲等;《药物分析杂志》;20061231;第26卷(第3期);第369-371页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104127417A (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105213346B (zh) | 一种含有盐酸西那卡塞的药物组合物及其制备方法 | |
WO2000078292A1 (fr) | Preparations solides a desintegration rapide | |
CN105287411A (zh) | 一种吡仑帕奈分散片及其制备方法 | |
CN105456270A (zh) | 一种二肽基肽酶ⅳ抑制剂药物组合物、其用途及其制备方法 | |
CN107913256A (zh) | 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法 | |
CN104586797A (zh) | 阿戈美拉汀分散片及其制备方法 | |
CN104127417B (zh) | 一种氨酚咖那敏片及其制备方法 | |
CN103251567B (zh) | 一种阿戈美拉汀片剂及其制备方法 | |
CN109925287A (zh) | 一种盐酸赛庚啶片剂及其制备方法 | |
CN109010298B (zh) | 一种二甲双胍格列吡嗪复方组合物及其制备方法 | |
EP3238712B1 (en) | Very rapidly disintegrating tablet, and method for producing same | |
JP2021075686A (ja) | セルロース組成物、錠剤及び口腔内崩壊錠 | |
CN104546779A (zh) | 高药物荷载的枸橼酸西地那非片剂及其制备方法 | |
CN104146977B (zh) | 一种泮托拉唑钠肠溶片及其制备方法 | |
CN107982237B (zh) | 一种盐酸索他洛尔制剂及其制备方法 | |
CN114129528B (zh) | 一种具有临床优势的新型枸橼酸西地那非制剂及其制备工艺与应用 | |
CN102626410A (zh) | 一种含有罗氟司特的药物组合物 | |
CN111686084B (zh) | 一种盐酸小檗碱谷维素片剂在治疗糖尿病中的应用 | |
CN113616613A (zh) | 一种治疗糖尿病用药二甲双胍格列吡嗪复方片剂及其制备方法 | |
CN103169706B (zh) | 一种含有对乙酰氨基酚和右美沙芬的复方口腔崩解片 | |
CN104127390B (zh) | 一种多潘立酮片及其制备工艺 | |
CN103301074A (zh) | 一种甘草酸二铵肠溶微丸及其制备方法和制剂 | |
CN113521021B (zh) | 一种含有富马酸卢帕他定的片剂及其制备方法 | |
CN102908377A (zh) | 一种益肝灵分散片及其制备方法 | |
CN103356501B (zh) | 一种利培酮片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Applicant after: LIAONING GREEN BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Applicant before: LIAONING GREEN BIO-PHARMACEUTICAL GROUP Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: Yuanyan Yaogang Biopharmaceutical (Shenyang) Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: Yuanyan Pharmaceutical Port Bioindustry (Liaoning) Group Co.,Ltd. Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: Yuanyan Pharmaceutical Port Bioindustry (Liaoning) Group Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: LIAONING GREEN BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |